Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Clinical outcomes of acute kidney injury patients treated in a single-center, sub-urban satellite hospital.

Authors:
Fariz Safhan Mohd Nor Che Rosle Draman Mohd Ramli Seman Norasmiza Abd Manaf Azril Shahreez Abd Ghani Khairul Anuar Hassan

Saudi J Kidney Dis Transpl 2015 Jul-Aug;26(4):725-32

Department of Internal Medicine, Kulliyyah of Medicine, International Islamic University Malaysia, Pahang, Malaysia.

Acute kidney injury (AKI) is a common diagnosis among critically ill patients. Although the etiology of AKI will determine the appropriate initial management, the definitive management of established AKI is still debatable. This is a retrospective, observational, single-center analysis of a cohort of patients referred to the nephrology unit for AKI from 1st August 2010 to 31st January 2011. Those patients with indications for dialysis were treated with continuous renal replacement therapy, intermittent hemodialysis or stiff-catheter peritoneal dialysis as determined by their hemodynamic status and the technical availability of the method. The 30-day mortality rate, renal outcomes and independent prognostic factors were analyzed statistically. Seventy-five patients were reviewed. The mean age was 52.9 ± 14.5 years. Two-thirds were males and 75% were Malays. 53.3% were referred from intensive wards. Pre-renal AKI and intra-renal AKI were diagnosed in 21.3% and 73.3% patients, respectively. Sepsis was the most common cause (n = 59). The pathogens were successfully cultured in 42.3% of the cases. The median urea and creatinine were 30.4 [interquartile range (IQR) 20.3] mmol/L and 474 (IQR 398.0) μmol/L, respectively. Seventy-six percent had metabolic acidosis. Oliguria was only noted in 38.7% of the patients. Sixty percent (n = 45) of the referrals were treated with conventional, intermittent hemodialysis and 22.7% (n = 17) with continuous veno-venous hemofiltration. The 30-day mortality rate was 28%, and was higher in intensive wards (37.5% versus 17.1%). Thirty-one percent (n = 20) had complete recovery, 17 (26.6%) had partial recovery without dialysis and seven (10.9%) became dialysis dependent. The 30-day mortality rate was 28%. Referral from intensive wards was the only significant poor prognostic factor in our patients and not the dialysis modalities.

Download full-text PDF

Source
http://dx.doi.org/10.4103/1319-2442.160273DOI Listing
July 2015

Publication Analysis

Top Keywords

mortality rate
12
intensive wards
12
30-day mortality
12
patients
8
kidney injury
8
intermittent hemodialysis
8
acute kidney
8
rate 28%
8
aki
6
dialysis
5
intra-renal aki
4
diagnosed 213%
4
aki intra-renal
4
aki diagnosed
4
pre-renal aki
4
213% 733%
4
referred intensive
4
533% referred
4
wards pre-renal
4
common pathogens
4

Similar Publications

Mid-regional pro atrial natriuretic peptide independently predicts short-term mortality in COVID-19.

Authors:
Christoph C Kaufmann Amro Ahmed Mona Kassem Matthias K Freynhofer Bernhard Jäger Gabriele Aicher Susanne Equiluz-Bruck Alexander O Spiel Georg-Christian Funk Michael Gschwantler Peter Fasching Johann Wojta Kurt Huber

Eur J Clin Invest 2021 Mar 3:e13531. Epub 2021 Mar 3.

3rd Medical Department with Cardiology and Intensive Care Medicine, Wilhelminenhospital Vienna, Austria.

Background: Mid-regional pro atrial natriuretic peptide (MR-proANP) is a strong prognostic marker in several inflammatory, respiratory and cardiovascular conditions, but has not been studied in COVID-19 yet.

Methods: This prospective, observational study of patients with COVID-19 infection was conducted from June 6 to November 26 , 2020 in different wards of a tertiary hospital. MR-proANP, N-terminal pro brain natriuretic peptide (NT-proBNP) and high-sensitive cardiac troponin I levels on admission were collected and tested for their association with disease severity and 28-day mortality. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Mortality and clinical response of patients with bullous pemphigoid treated with rituximab.

Authors:
D S Yoo J H Lee S-C Kim J H Kim

Br J Dermatol 2021 Mar 3. Epub 2021 Mar 3.

Department of Dermatology, Gangnam Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.

Bullous pemphigoid (BP) is one of the most common autoimmune bullous diseases characterized by autoantibodies targeting BP230 and BP180. BP usually occurs in individuals over 70 years of age and shows a high mortality rate. In the meta-analysis, the 1-year mortality rate of BP patients was reported to be 23. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Tetanus, Diphtheria, Acellular Pertussis Vaccination During Pregnancy and Risk of Pertussis in the Newborn in Publicly and Privately Insured Mother-infant Pairs in the United States.

Authors:
Katrina Mott Krista F Huybrechts Robert J Glynn Helen Mogun Sonia Hernández-Díaz

Pediatr Infect Dis J 2021 Mar 2. Epub 2021 Mar 2.

From the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts Division of Pharmacoepidemiology & Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Background: In the United States, pertussis circulation persists and primarily infects infants and children, despite routine vaccinations. To minimize infant morbidity and mortality from the disease before the first DTaP dose, the Advisory Committee on Immunization Practices recommends maternal Tdap vaccination in weeks 27-36 of pregnancy.

Methods: Cohorts of mother-infant pairs in the Medicaid Analytic eXtract (MAX) (2010-2014) and IBM MarketScan (2011-2015) databases were analyzed to estimate the effectiveness of prenatal Tdap vaccination compared to no vaccination to prevent infant pertussis in the first 6 months. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs-Findings From the BIOCOVID Study.

Authors:
Santiago Muñoz-Fernández Laura Cebrian Israel John Thuissard Martina Steiner Cristina García-Yubero Ana Victoria Esteban Fernando Sánchez Alejandro Gómez Maria Angeles Matías Tatiana Cobo-Ibáñez Mar Esteban Noemí Manceñido Ramón Pajares María Rosario Arribas Alicia Martínez Cristina Andreu Concepción Esteban Liz Romero Teresa Navío

J Clin Rheumatol 2021 Mar 5. Epub 2021 Mar 5.

From the Rheumatology Section, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid Rheumatology Section, Hospital Universitario Infanta Leonor Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid Pharmacy Section, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid Rheumatology Section, Hospital Universitario Infanta Sofía Ophthalmology Section Gastroenterology Section, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid Pharmacy Service Rheumatology Section, Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid, Madrid, Spain.

Objectives: The aim of this study was to examine the incidence of coronavirus disease 2019 (COVID-19) among patients with immunomediated inflammatory diseases (IMIDs) treated with biologic or targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) and to evaluate the influence of either IMIDs or related therapies on the incidence and evolution of COVID-19.

Methods: This observational, cross-sectional study was conducted from January 31, 2020, to May 15, 2020. Data of 902 patients were obtained from clinical records in hospitals, primary care units, and community pharmacies. Read More

View Article and Full-Text PDF
March 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap